Semaglutide and medically supervised weight loss

How does semaglutide cause weight loss?

Semaglutide is a synthetic analogue of GLP-1, a hormone released by the gut after eating. It acts on appetite centres in the hypothalamus and brainstem to increase satiety and reduce hunger, and it slows gastric emptying so that a meal produces fullness sooner and for longer. The net effect is a substantial reduction in food intake that the patient does not have to sustain by willpower.^[1]

This matters because appetite, not motivation, is the reason most diets fail. Weight loss lowers leptin and raises ghrelin, and the resulting increase in hunger persists for years after the weight is lost — a biological counter-attack that is very difficult to overcome by resolve alone. GLP-1 therapy works by acting on that mechanism directly, which is why it succeeds where dietary advice alone often does not.

Who is a candidate for semaglutide?

Body-mass index thresholds for South Asians are lower than international ones, because metabolic risk appears at lower body weight. Under the Indian consensus, overweight begins at a BMI of 23 and obesity at 25, with waist circumference cut-offs of 90 cm in men and 80 cm in women.^[2] Medical weight-loss therapy is generally considered at a BMI of 27.5 or above where there is a weight-related condition — type 2 diabetes, fatty liver, hypertension, obstructive sleep apnoea, PCOS — or at a BMI of 30 or above.

Semaglutide is an addition to reduced-calorie eating and physical activity, not a replacement for them. It is avoided in anyone with a personal or family history of medullary thyroid carcinoma or MEN-2, is used cautiously where there has been pancreatitis or significant gallbladder disease, and is not used in pregnancy or while trying to conceive. Adequate protein intake and resistance activity during treatment matter, because rapid weight loss costs muscle as well as fat if it is not managed.

How does the programme work at Uttarbanga Clinic?

Treatment is individualised and monitored rather than a fixed prescription. Baseline assessment includes body composition analysis measuring fat mass, muscle mass and visceral fat, along with HbA1c, lipids, liver function, kidney function and thyroid function. Dose escalation then follows a schedule adjusted to tolerance, and body composition is repeated during treatment so that progress is judged as fat lost and muscle preserved, rather than by the scale alone.

How does semaglutide compare with other weight-loss medicines?

Semaglutide is not the only option, and it is not the most effective one. The figures below are mean results from pivotal trials, and individual response varies widely — a meaningful minority of patients lose very little on any given agent.

What are the side effects?

The commonest side effects are gastrointestinal: nausea, early fullness, belching, constipation and occasionally loose stools. They are typically mild, appear after each dose increase, and settle within a few weeks. Slow titration is the main way they are minimised, and holding at a dose for longer is usually better than pushing through. Eating smaller portions, avoiding fatty and fried food, and stopping when full rather than when the plate is empty all help.

Less common but more serious concerns include pancreatitis, gallstones — which become more likely with rapid weight loss of any cause — and, in people with existing diabetic retinopathy, a transient worsening of retinopathy when glucose falls quickly. Semaglutide is contraindicated where there is a personal or family history of medullary thyroid carcinoma or MEN-2. Regular review during treatment exists precisely to catch these.

What happens if I stop taking it?

Weight is commonly regained. In the STEP 1 extension study, participants who stopped semaglutide regained about two-thirds of the weight they had lost within a year, and cardiometabolic improvements reverted with it.^[3] This is not a failure of the drug or of the patient; it is what happens when a treatment that acts on appetite is withdrawn and the underlying biology reasserts itself. Obesity behaves like a chronic condition in this respect, in the same way blood pressure does. Anyone considering starting should understand at the outset that this is likely to be long-term treatment, and should factor the ongoing cost into the decision. That conversation happens before the first prescription, not after.